Tempus AI, Inc. (TEM) Secures EU IVDR Class C Certification for xR

What happened

Tempus AI received EU IVDR Class C certification for its xR RNA sequencing assay, which profiles solid tumors. The certification supports European Union access beyond 2028 and gives biopharma partners an IVDR-certified platform for clinical studies.

Confirmed

Global impact / market context

The certification lets Tempus keep selling xR in Europe after the 2028 transition deadline for older devices, reducing regulatory continuity risk. It may also help win biopharma study work and companion diagnostic projects, which supports testing revenue and partnership income.

Analyst inference

This is a mid-cycle regulatory step in Tempus' push to grow clinical diagnostics and biopharma services in Europe. Investors would likely need disclosed contracts, adoption metrics, or revenue figures tied to IVDR-certified xR deployment to treat it as a larger catalyst.

Analyst inference

What to watch

1. The article says a larger catalyst would be disclosed contracts, adoption metrics, or revenue impact tied to IVDR-certified xR deployment; watch whether Tempus discloses any of these. Confirmed
2. Watch for Tempus announcements about biopharma partners using xR as an IVDR-certified platform in clinical studies, which could support partnership revenue and trial enrollment. Proposed
3. Watch clinician demand for xR, since the article suggests RNA plus DNA testing finds more actionable fusions, which may increase use in oncology testing workflows and support revenue. Analyst inference

Evidence

• Original source link unavailable